Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02216890 | Safety Study of SGN-CD70A in Cancer Patients | completed | Phase 1 | 38 | Seagen Inc.INDUSTRY | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00807495 | Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 48 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 27, 2018 | clinicaltrials |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | completed | Phase 1 / Phase 2 | 45 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | Mar 27, 2018 | clinicaltrials |
| NCT00201877 | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00963534 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.(LENA-BERIT) | completed | Phase 1 / Phase 2 | 51 | Lund University HospitalOTHER | 4 | Mar 12, 2018 | clinicaltrials |
| NCT01737177 | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL(R2-B) | completed | Phase 2 | 42 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT00253630 | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2018 | clinicaltrials |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | completed | Phase 3 | 447 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 7 | Feb 5, 2018 | clinicaltrials |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | completed | Phase 1 | 90 | Celldex TherapeuticsINDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02142530 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00186628 | Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD | completed | Phase 2 | 36 | Stanford UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01562977 | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL(RGemOx) | completed | Phase 2 | 82 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | completed | Phase 2 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01786135 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | completed | Phase 1 | 64 | Seagen Inc.INDUSTRY | 1 | Oct 19, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT01078142 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma(BERT) | completed | Phase 1 / Phase 2 | 39 | Georg Hess, MDOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00472420 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00446342 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | completed | Phase 1 | 21 | Sunesis PharmaceuticalsINDUSTRY | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00408681 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant(GVHD) | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT03054883 | Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy | completed | — | 73 | Czech Lymphoma Study GroupOTHER | 0 | Feb 16, 2017 | clinicaltrials |
| NCT01475058 | CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant | completed | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01300026 | AMG 319 Lymphoid Malignancy FIH | completed | Phase 1 | 28 | AmgenINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00633594 | Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 39 | SCRI Development Innovations, LLCOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT02341781 | Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment(MCL-004) | completed | — | 30 | CelgeneINDUSTRY | 4 | Jan 26, 2017 | clinicaltrials |
| NCT02169180 | Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 16 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT00656084 | Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell | completed | Phase 2 | 16 | US Oncology ResearchINDUSTRY | 0 | Nov 3, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT00607854 | Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)(ZEVALLO) | completed | Phase 2 | 31 | University Hospital, BordeauxOTHER | 1 | Oct 5, 2016 | clinicaltrials |
| NCT00786851 | Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 2 | 33 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00407303 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 24 | Gemin XINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT01599949 | A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | completed | Phase 2 | 120 | Janssen Research & Development, LLCINDUSTRY | 9 | Jun 1, 2016 | clinicaltrials |
| NCT01367457 | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus | completed | — | 243 | PfizerINDUSTRY | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01457144 | Study of Mantle Cell Lymphoma Treatment by RiBVD(RIBVD) | completed | Phase 2 | 76 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00438880 | Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 19, 2018source: clinicaltrials